Bicara Therapeutics: Wedbush cuts target price to $24 from $33
BCAX•Wedbush cut its target price for Bicara Therapeutics to $24 from $33.
Related News
JPMorgan Asset Management, affiliates cut Eugene Technology stake to 5% from 6.48%
JPM•
Dana Inc: RBC cuts target price to $32 from $37
DAN•
Fiverr Q3 2026 net income drops 77% year over year to $1.27 million
FVRR•
Indonesia's rupiah gains on high bond yields; Asian FX steady after Fed hold
TLT•
MediaAlpha, Inc.: KBW raises target price to $16.00 from $14.00
MAX•